This technology enables safer administration of radioligand therapies, allowing for healthier, lower radiation doses to both patients and administering staff.
Background: At present, there are two FDA-approved radioligand therapies for broad use in cancer treatment: Lutathera (177Lutetium DOTATATE) and Pluvicto (177Lutetium Vipivotide Tetraxetan). Pluvicto is dispensed from the pharmaceutical distributor in a 20cc syringe for intravenous injection. Currently, there is no way to allow physicians to hold this syringe within a syringe shield while administering the dose. And even with lead-lined gloves, the radiation the physician absorbs during the two-minute injection can be significant. Further, the syringe shield is not secure when grasped with lead-lined gloves. As a result, there is a tradeoff between secure administration and radiation exposure dose.
Technology Overview: This technology is a physical support device for safely administering radioligand therapies. This device, called a dose caddy, allows the syringe and syringe shield to fit snugly onto a larger physical mount that can fit onto a standard clinical tabletop. The syringe plunger extension rod and set up of the dose caddy minimize the radiation dose to the administering physician, while allowing safe, controlled delivery of the radiopharmaceutical to the patient. The dose caddy is printed via tabletop 3D printer, with ABS (Acrylonitrile Butadiene Styrene) or PLA (Polylactic Acid) as the printing material. This device is highly configurable to any clinical setting and allows for safer, lower radiation doses to both patients and administering staff.
https://suny.technologypublisher.com/files/sites/adobestock_255606405.jpeg
Advantages: • Protects physician from radiation during administration of radioligand therapies. • Provides better control of syringe compared to using lead-lined gloves with a syringe shield. • Highly configurable to the clinical setting. • Can be fabricated via 3D printer, using common materials.
Applications: The primary application for this technology is safer administration of radioligand therapies.
US Non-Provisional Filed: 19/394,230
Stage of Development: TRL 6
Licensing Status: This technology is available for licensing.